Skip to main content
padlock icon - secure page this page is secure

Prognostic markers in core‐binding factor AML and improved survival with multiple consolidation cycles of intermediate‐/high‐dose cytarabine

Buy Article:

$59.00 + tax (Refund Policy)

Core‐binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for relapse in a de novo CBF AML cohort.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: acute myeloid leukaemia; core‐binding factors; prognosis

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more